Annals of Oncology 7:165-171, 1996
© 1996 European Society for Medical Oncology
research-article |
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC*
1Centre Régionale de Lutte Contre le Cancer, Nantes Atlantique-ICERC Saint Herblain
2Centre Henn Becquerel Rouen
3Centre Eugene Marquis Pontchaillou, Rennes
4Centre Alexis Vautrin Vandoeuvre les Nancy
5Hôpital Paul Brousse - SMST Villejuif
6Institut Curie Paris
7Rhône-Poulenc Rorer, Research and Development Antony
8Centre Claudius Regaud Toulouse, France
Pierre Fumoleau, M.D. Centre Regionale de Lutte Contre le Cancer Nantes Atlantique-ICERC Boulevard Jacques Monod 44805 St. Herblain Cedex, France
Background: Two previous phase II trials of docetaxel as first line chemotherapy of advanced breast cancer have been conducted by the Clinical Screening Group of the EORTC. In these 2 studies, docetaxel 100 mg/m2 and 75 mg/m2 were administered without routine premedication and produced overall response rates of 68% and 52% respectively. Fluid retention was the most problematic adverse event in these 2 studies in which premedication was not routinely administered. This study investigated the efficacy and safety profile of docetaxel with a 1-day prophylactic premedication.
Patients and methods: Docetaxel 100 mg/m2 was administered intravenously over 1 hour, every 3 weeks, to 37 women (aged 29–65 years) with advanced breast cancer. A 1-day regimen of intravenous antihistamine and oral corticoster-oids was given with each dose. Full doses of docetaxel were administered in 179 of 200 cycles (89.5%), giving a median relative dose intensity of 0.98.
Results: Tumour regression was achieved in 25 patients (67.6%) after a median of 7 weeks, and 2 patients (5.4%) had a complete response. Response rates were 67.9% in patients with visceral metastases, 76.9% in liver metastases and 83.3% in patients with > 2 organs involved. The median time to progression was 31 weeks (range 1–36+). After a median follow-up time of 6.9 months (range 4.6–9.4), 31 patients (83.7%) were still alive.
The most common adverse events (AE) were neutropenia (97%), alopecia (97%, grade 1–2), fluid retention (89%, mainly mild to moderate) and neurosensory disorders (81%, mainly mild to moderate). Only 5 patients experienced febrile neutropenia requiring hospitalisation and/or antibiotic therapy. Sixteen patients discontinued treatment because of fluid retention; nevertheless, 13 of these achieved an objective antitumour response and none had any significant deterioration in performance status. AEs were generally reversible and easily managed, and there were no deaths attributable to docetaxel-related AEs.
Conclusions: Docetaxel produces very effective tumour response with acceptable tolerability when used as first-line chemotherapy in patients with advanced breast cancer. The 1-day premedication regimen used in this study was less effective in reducing the incidence and severity or delaying the onset of fluid retention than the currently recommended 5-day corticosteroid premedication. The optimum premedication regimen remains to be defined.
anticancer chemotherapy, breast cancer-locally advanced, breast cancer-metastatic, docetaxel, taxoids
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. E. Langley, J. Carmichael, A. L. Jones, D. A. Cameron, W. Qian, B. Uscinska, A. Howell, and M. Parmar Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01 J. Clin. Oncol., November 20, 2005; 23(33): 8322 - 8330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bontenbal, G.-J. Creemers, H. J. Braun, A. C. de Boer, J. Th. Janssen, R. B. Leys, J. B. Ruit, S. H. Goey, P. C. van der Velden, L. G. Kerkhofs, et al. Phase II to III Study Comparing Doxorubicin and Docetaxel With Fluorouracil, Doxorubicin, and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre J. Clin. Oncol., October 1, 2005; 23(28): 7081 - 7088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.R. J. Evans, A. Yellowlees, E. Foster, H. Earl, D. A. Cameron, A. W. Hutcheon, R. E. Coleman, T. Perren, C. J. Gallagher, M. Quigley, et al. Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study J. Clin. Oncol., May 1, 2005; 23(13): 2988 - 2995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cresta, G. Grasselli, M. Mansutti, A. Martoni, G. Lelli, G. Capri, F. Buzzi, G. Robustelli Della Cuna, A. Jirillo, E. Terzoli, et al. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer Ann. Onc., March 1, 2004; 15(3): 433 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Nabholtz, C. Falkson, D. Campos, J. Szanto, M. Martin, S. Chan, T. Pienkowski, J. Zaluski, T. Pinter, M. Krzakowski, et al. Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial J. Clin. Oncol., March 15, 2003; 21(6): 968 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Perez, L. Geeraerts, V. J. Suman, A. A. Adjei, A. T. Baron, A. K. Hatfield, N. Maihle, J. C. Michalak, S. A. Kuross, J. W. Kugler, et al. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer Ann. Onc., August 1, 2002; 13(8): 1225 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Aihara, Y. Kim, and Y. Takatsuka Phase II study of weekly docetaxel in patients with metastatic breast cancer Ann. Onc., February 20, 2002; 13(2): 286 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jassem, T. Pienkowski, A. Pluzanska, S. Jelic, V. Gorbunova, Z. Mrsic-Krmpotic, J. Berzins, T. Nagykalnai, N. Wigler, J. Renard, et al. Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial J. Clin. Oncol., March 15, 2001; 19(6): 1707 - 1715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Crown and W. Palmby Docetaxel: use in non--small cell lung cancer and metastatic breast cancer and formulation update Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3_suppl): S11 - S21. [Abstract] [PDF]
|
|
|
|
|
|
H. J. Burstein, J. Manola, J. Younger, L. M. Parker, C. A. Bunnell, R. Scheib, U. A. Matulonis, J. E. Garber, K. D. Clarke, L. N. Shulman, et al. Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer J. Clin. Oncol., March 13, 2000; 18(6): 1212 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Vogel and J.-M. Nabholtz Monotherapy of Metastatic Breast Cancer: A Review of Newer Agents Oncologist, February 1, 1999; 4(1): 17 - 33. [Abstract] [Full Text]
|
|
|
|
 |
|
 {blacktriangledown}Paclitaxel and {blacktriangledown}docetaxel in breast and ovarian cancer DTB, June 1, 1997; 35(6): 43 - 46. [Abstract] [Full Text] [PDF]
|
|